Protocolli GOIRC-sponsored con arruolamento aperto

GOIRC-03-2019 ATEZOMESO

PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION

Centro Coordinatore: Reggio Emilia

GOIRC-01-2021 DURVASCC

AGNOSTIC THERAPY IN A PHASE II, MULTICENTER, SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB (MEDI 4736) IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (EPSCC) – DURVASCC TRIAL

Centro Coordinatore: Reggio Emilia

GOIRC-01-2022 HEROS (osservazionale)

HER2 aberrations in advanced NSCLC: an Observational, retrospective and prospective, multi-centric Study exploring HER2 alterations incidence and therapeutic management in Italy. The HEROS study.

Centro Coordinatore: Parma

GOIRC-01-2023  CARRY-ON

Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line platinum-etoposide chemotherapy and a PD-L1 inhibitor: CARRY-ON study - GOIRC-01-2023

Centro Coordinatore: Bologna

GOIRC-02-2024 IMMUNOSTAR

Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial  -  GOIRC-02-2024

Centro Coordinatore: Reggio Emilia

GOIRC-03-2024 REMAIN (osservazionale)

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in radically resected EGFR-mutated NSCLC patients: REMAIN trial

Centro Coordinatore: Parma

GOIRC-06-2024 PROBreast (osservazionale)

Mobile App to enhance engagement and communication with metastatic breast cancer patients: a feasibility study. PROBreast-GOIRC-06-2024

Centro Coordinatore: Meldola